United States vs. China: The CAR T-Cell Therapy Landscape & Comparative Analysis

T-cell Therapy

Researchers from the Office of Clinical Evaluation of Biological Products, Center for Drug Evaluation, China Food and Drug Administration recently produced a report titled “The Landscape of Car T-cell Therapy in the United States and China: A comparative analysis,” published in the International Journal of Cancer.
China has rapidly emerged as a viable center of novel innovation in cancer research and development. Three of the four authors work for the Chinese regulatory authority and hence posses a strategic perspective on the emergence of this new class of treatment as it unfolds in both critically important countries.
Introduction to the Research
They note that clinical trials of CAR T-cell therapy are rapidly growing in both the United States and China. They emphasize that exhibiting the distinctions between the clinical trials in the two countries is of great value for understanding the panorama of CAR T-cell clinical trials and forecasting the future of this promising therapy.
The authors analyzed the critical elements of 289 clinical trials posted on the Clinicaltrials.gov website by sponsors from the two countries—they evaluated the efficacy data in the availabl...

Note:  If you need assistance with your subscription or would like to discuss a corporate subscription for more than 10 employees please contact us or use the chat (bottom right).

$5 / Month
Individuals at home that are reading our content for personal health care or other non-professional reasons.
Like a Starbucks a month
Personal - Single Payment
$50 for 1 Year
Individuals - reading for personal reasons who prefer to pay for one year in advance with no recurring billing.
18% discount to monthly
$12 / Month
Professionals from the healthcare industry who are subscribing on behalf of their company for work reasons.
Way better than coffee